Flortaucipir (tau) PET in LGI1 antibody encephalitis

Gregory Day; Brian A. Gordon; Austin McCullough; Robert C. Bucelli; Richard J. Perrin; Tammie L.S. Benzinger; Beau M. Ances

doi:10.1002/acn3.51297

Flortaucipir (tau) PET in LGI1 antibody encephalitis

Gregory Day, Brian A. Gordon, Austin McCullough, Robert C. Bucelli, Richard J. Perrin, Tammie L.S. Benzinger, Beau M. Ances

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The contributors to persistent cognitive impairment and hippocampal atrophy in leucine-rich glioma-inactivated 1 antibody encephalitis (LGI1) patients are unknown. We evaluated whether tau neuropathology measured with [¹⁸F]flortaucipir PET neuroimaging associated with persistent cognitive impairment and hippocampal atrophy in four recovering LGI1 patients (3 men; median age, 67 [37–88] years). Imaging findings in cases were compared with those observed in age- and gender-similar cognitively normal individuals (n = 124) and individuals with early-symptomatic Alzheimer disease (n = 11). Elevated [¹⁸F]flortaucipir retention was observed in the two LGI1 patients with hippocampal atrophy and persistent cognitive impairment, including one with autopsy-confirmed Alzheimer disease. Tau neuropathology may associate with cognitive complaints and hippocampal atrophy in recovering LGI1 patients.

Original language	English
Pages (from-to)	491-497
Number of pages	7
Journal	Annals of Clinical and Translational Neurology
Volume	8
Issue number	2
DOIs	https://doi.org/10.1002/acn3.51297
State	Published - Feb 2021

Access to Document

10.1002/acn3.51297

Cite this

@article{490c3919ab974d0688b3e201676d461e,

title = "Flortaucipir (tau) PET in LGI1 antibody encephalitis",

abstract = "The contributors to persistent cognitive impairment and hippocampal atrophy in leucine-rich glioma-inactivated 1 antibody encephalitis (LGI1) patients are unknown. We evaluated whether tau neuropathology measured with [18F]flortaucipir PET neuroimaging associated with persistent cognitive impairment and hippocampal atrophy in four recovering LGI1 patients (3 men; median age, 67 [37–88] years). Imaging findings in cases were compared with those observed in age- and gender-similar cognitively normal individuals (n = 124) and individuals with early-symptomatic Alzheimer disease (n = 11). Elevated [18F]flortaucipir retention was observed in the two LGI1 patients with hippocampal atrophy and persistent cognitive impairment, including one with autopsy-confirmed Alzheimer disease. Tau neuropathology may associate with cognitive complaints and hippocampal atrophy in recovering LGI1 patients.",

author = "Gregory Day and Gordon, {Brian A.} and Austin McCullough and Bucelli, {Robert C.} and Perrin, {Richard J.} and Benzinger, {Tammie L.S.} and Ances, {Beau M.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.",

year = "2021",

month = feb,

doi = "10.1002/acn3.51297",

language = "English",

volume = "8",

pages = "491--497",

journal = "Annals of Clinical and Translational Neurology",

issn = "2328-9503",

number = "2",

}

TY - JOUR

T1 - Flortaucipir (tau) PET in LGI1 antibody encephalitis

AU - Day, Gregory

AU - Gordon, Brian A.

AU - McCullough, Austin

AU - Bucelli, Robert C.

AU - Perrin, Richard J.

AU - Benzinger, Tammie L.S.

AU - Ances, Beau M.

PY - 2021/2

Y1 - 2021/2

N2 - The contributors to persistent cognitive impairment and hippocampal atrophy in leucine-rich glioma-inactivated 1 antibody encephalitis (LGI1) patients are unknown. We evaluated whether tau neuropathology measured with [18F]flortaucipir PET neuroimaging associated with persistent cognitive impairment and hippocampal atrophy in four recovering LGI1 patients (3 men; median age, 67 [37–88] years). Imaging findings in cases were compared with those observed in age- and gender-similar cognitively normal individuals (n = 124) and individuals with early-symptomatic Alzheimer disease (n = 11). Elevated [18F]flortaucipir retention was observed in the two LGI1 patients with hippocampal atrophy and persistent cognitive impairment, including one with autopsy-confirmed Alzheimer disease. Tau neuropathology may associate with cognitive complaints and hippocampal atrophy in recovering LGI1 patients.

AB - The contributors to persistent cognitive impairment and hippocampal atrophy in leucine-rich glioma-inactivated 1 antibody encephalitis (LGI1) patients are unknown. We evaluated whether tau neuropathology measured with [18F]flortaucipir PET neuroimaging associated with persistent cognitive impairment and hippocampal atrophy in four recovering LGI1 patients (3 men; median age, 67 [37–88] years). Imaging findings in cases were compared with those observed in age- and gender-similar cognitively normal individuals (n = 124) and individuals with early-symptomatic Alzheimer disease (n = 11). Elevated [18F]flortaucipir retention was observed in the two LGI1 patients with hippocampal atrophy and persistent cognitive impairment, including one with autopsy-confirmed Alzheimer disease. Tau neuropathology may associate with cognitive complaints and hippocampal atrophy in recovering LGI1 patients.

UR - http://www.scopus.com/inward/record.url?scp=85099064194&partnerID=8YFLogxK

U2 - 10.1002/acn3.51297

DO - 10.1002/acn3.51297

M3 - Article

C2 - 33410601

AN - SCOPUS:85099064194

SN - 2328-9503

VL - 8

SP - 491

EP - 497

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

IS - 2

ER -

Flortaucipir (tau) PET in LGI1 antibody encephalitis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this